Resistance to fluoroquinolones and second-line injectable drugs: Impact on multidrug-resistant TB outcomes

European Respiratory Journal

Volumn 42, Issue 1, 2013, Pages 156-168

  Falzon, D ^m   Gandhi, N ^m   Migliori, G B ⁿ   Sotgiu, G ^m   Cox, Helen S ^a   Holtz, T H ^m   Hollm Delgado, M G ^m   Keshavjee, S ^m   DeRiemer, Kathryn ^h,m   Centis, R ⁿ   D'Ambrosio, L ⁿ   Lange, Christoph G ⁱ   Bauer, M ^m   Menzies, D ^m   Ahuja, S D ^k   Ashkin, D ^l   Avendano M ^m   Banerjee, R ^m   Becerra, M C ^m   Benedetti, A ^m   Burgos, M ^m   Chan, E D ^m   Chiang, C Y ^o   Cobelens, F ^m   Cox, H ^m   De Lange, W C M ^m   Enarson, D ^m   Flanagan, K L ^p   Flood, J ^m   Garcia Garcia, M L ^q   Granich, R M ^m   Hopewell, P ^m   Iseman, M D ^m   Jarlsberg, L G ^m   Kim, H R ^m   Koh, W J ^m   Lancaster, J L ^m   Lange, C ^m   Leimane, V ^r   Leung, C C ^m   Li, J ^m   Mitnick, C D ^m   Narita, M ^m   Nathanson, E ^s   Odendaal, R ^s   O'Riordan, P ^s   Pai, M ^m   Palmero, D ^m   Park, S K ^m   Pasvol, G ^s   Pena, J M ^m   Perez Guzman C ^t   Ponce De Leon, A ^u   Quelapio, M I D ^m   Quy, H T ^r   Riekstina, V ^r   Robert, J ^m   Royce, S ^m   Salim, M ^m   Schaaf, H S ^m   Seung, K J ^m   Shah, L ^m   Shean, K ^m   Shim, T S ^m   Shin, S S ^m   Shiraishi, Y ^m   Sifuentes Osornio, J ^u   Strand, M J ^m   Sung, S W ^m   Tabarsi, P ^m   Tupasi, T E ^m   Vargas, M H ^u   Van Altena, R ^m   Van Der Walt, M L ^m   Van Der Werf, T S ^m   Viiklepp, P ^m   Westenhouse, J ^m   Yew, W W ^m   Yim, J J ^m   more..

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SASSARI   (Italy)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h Tuberculosis Center Borstel   (Germany)

ⁱ MCGILL UNIVERSITY   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k NONE   (United States)

^l NONE   (United States)

^m NONE   (Estonia)

ⁿ Tradate Hospital   (Italy)

^o DEPARTMENT OF HEALTH   (Taiwan)

^p Vaccinology Department Medical Research Council Unit   (Gambia)

^q Cuernavaca   (Mexico)

^r NONE   (Latvia)

^s London   (United Kingdom)

^t Aguascalientes   (Mexico)

^u Autonom University of Mexico city   (Mexico)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; TERIZIDONE; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; IMIPENEM; LINEZOLID; MACROLIDE; PROTIONAMIDE; ROXITHROMYCIN; THIOACETAZONE; UNINDEXED DRUG;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CAUSE OF DEATH; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RELAPSE; SECONDARY HEALTH CARE; TREATMENT DURATION; TREATMENT OUTCOME; DEATH; DRUG MEGADOSE; DRUG RESPONSE; METHODOLOGY; MULTIDRUG RESISTANCE; OBSERVATIONAL STUDY;

EID: 84880162469     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00134712     Document Type: Article

References (67)

1. Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. BMJ 1948; 2: 1009-1015.
2. Crofton J. The chemotherapy of tuberculosis. With special reference to patients whose bacilli are resistant to the standard drugs. Br Med Bull 1960; 16: 55-60.
3. Crofton J. Drug treatment of tuberculosis. II. Treatment of patients with tubercle bacilli resistant to standard chemotherapy. BMJ 1960; 2: 449-451.
4. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. Geneva, WHO Press, 2011.
5. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
6. World Health Organization. Global tuberculosis control: WHO report 2011. Geneva, WHO Press, 2011.
7. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111D-119D.
8. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580. (Pubitemid 44780738)
9. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
10. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010; 36: 584-593.
11. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, emergency update 2008. Geneva, WHO Press, 2008.
12. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, WHO Press, 2010.
13. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
14. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.
15. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
16. Akçakir Y. Correlates of treatment outcomes of multidrug-resistant tuberculosis (MDR-TB): a systematic review and meta-analysis. MSc Thesis. McGill University: Montréal, Canada. 2010.
17. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645. (Pubitemid 40826156)
18. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva, WHO Press, 2011.
19. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Oxford, The Cochrane Collaboration, 2011. www.cochrane-handbook. org Date last accessed: April 30, 2011. Date last updated: March 2011.
20. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
21. Thompson SG, Turner RM, Warn DE. Multilevel models for meta-analysis, and their application to absolute risk differences. Stat Methods Med Res 2001; 10: 375-392. (Pubitemid 33103814)
22. Turner RM, Omar RZ, Yang M, et al. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med 2000; 19: 3417-3432. (Pubitemid 32056694)
23. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558. (Pubitemid 34746062)
24. Avendaño M, Goldstein R. Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients. Can Respir J 2000; 7: 383-389.
25. Burgos M, Gonzalez LC, Paz EA, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40: 968-975. (Pubitemid 40418303)
26. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109. (Pubitemid 38624789)
27. Chiang C-Y, Enarson DA, Yu M-C, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006; 28: 980-985. (Pubitemid 46331968)
28. Cox HS, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One 2007; 2: e1126.
29. DeRiemer K, García-García L, Bobadilla-del-Valle M, et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005; 365: 1239-1245. (Pubitemid 40469656)
30. Escudero E, Peña JM, Alvarez-Sala R, et al. Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Int J Tuberc Lung Dis 2006; 10: 409-414.
31. Geerligs WA, Van Altena R, De Lange WCM, et al. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-764. (Pubitemid 30650034)
32. Granich RM, Oh P, Lewis B, et al. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005; 293: 2732-2739. (Pubitemid 40965085)
33. Holtz TH, Lancaster J, Laserson KF, et al. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006; 10: 649-655. (Pubitemid 43845026)
34. Kim DH, Kim HJ, Park S-K, et al. Treatment outcomes and long-term survival in patients with extensively drugresistant tuberculosis. Am J Respir Crit Care Med 2008; 178: 1075-1082.
35. Kim H-R, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIVinfected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295. (Pubitemid 351418994)
36. Kwon YS, Kim YH, Suh GY, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008; 47: 496-502.
37. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326. (Pubitemid 40139109)
38. Lockman S, Kruuner A, Binkin N, et al. Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis. Clin Infect Dis 2001; 32: 373-380. (Pubitemid 32173622)
39. Masjedi MR, Tabarsi P, Chitsaz E, et al. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006. Int J Tuberc Lung Dis 2008; 12: 750-755. (Pubitemid 351976704)
40. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626. (Pubitemid 351194820)
41. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128. (Pubitemid 36056718)
42. Munsiff SS, Ahuja SD, Li J, et al. Public-private collaboration for multidrug-resistant tuberculosis control in New York City. Int J Tuberc Lung Dis 2006; 10: 639-648. (Pubitemid 43845025)
43. Narita M, Alonso P, Lauzardo M, et al. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 2001; 120: 343-348. (Pubitemid 32881245)
44. O'Riordan P, Schwab U, Logan S, et al. Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: case control study. PLoS One 2008; 3: e3173.
45. Palmero DJ, Ambroggi M, Brea A, et al. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 2004; 8: 778-784. (Pubitemid 38747156)
46. Park SK, Lee WC, Lee DH, et al. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8: 361-368. (Pubitemid 38624874)
47. Pérez-Guzmán C, Vargas MH, Martínez-Rossier LA, et al. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis 2002; 6: 1102-1109. (Pubitemid 36054965)
48. Quy HT, Cobelens FGJ, Lan NTN, et al. Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis 2006; 10: 45-51. (Pubitemid 43266276)
49. Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. Arch Dis Child 2003; 88: 1106-1011.
50. Shin SS, Pasechnikov AD, Gelmanova IY, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006; 10: 402-408.
51. Shiraishi Y, Nakajima Y, Katsuragi N, et al. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis. J Thorac Cardiovasc Surg 2004; 128: 523-528. (Pubitemid 39278385)
52. Tupasi TE, Gupta R, Quelapio MID, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006; 3: e352.
53. Uffredi M-L, Truffot-Pernot C, Dautzenberg B, et al. An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agents 2007; 29: 434-439. (Pubitemid 46349593)
54. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-1481. (Pubitemid 37290060)
55. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000; 117: 744-751. (Pubitemid 30152215)
56. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430. (Pubitemid 16126276)
57. Kim DH, Kim HJ, Park S-K, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 113-119.
58. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrugresistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
59. Brossier F, Veziris N, Aubry A, et al. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 1683-1689.
60. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010; 14: 275-281.
61. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1456-1466.
62. World Health Organization. Resolution WHA62.15. Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. In: Sixty-second World Health Assembly: Resolutions and Decisions, Annexes. Geneva, World Health Organization, 2009. Available from: apps.who.int/gb/ebwha/ pdf-files/WHA62-REC1/WHA62-REC1-en.pdf Date last accessed April 11, 2012.
63. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366: 2161-2170.
64. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926. (Pubitemid 351632017)
65. Sirgel FA, Warren RM, Streicher EM, et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67: 1088-1093.
66. World Health Organization. Global tuberculosis report 2012. Geneva, WHO Press, 2012.
67. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.